Podcast Episodes
Back to Search
Lilly Expands Breast Cancer Choices & Novo Signs for Three Obesity Programs
Season 1
FDA fully approved Lilly's Inluriyo (imlunestrant) plus Verzenio (abemaciclib) after progression in ESR1-mutated advanced breast cancer; evidence is …
15 hours ago
Ultragenyx Wins Sanfilippo Type A Approval & Xenon Pauses New Psychiatry Enrollment
Season 1
Ultragenyx's Fayuvi approval opens a first treatment path for eligible children with Sanfilippo syndrome type A, with preserved function and center a…
1 day, 1 hour ago
Skyhawk's Early Huntington Signal Faces a Bigger Test & Sling Raises $123M
Season 1
Skyhawk's early SKY-0515 Huntington's signal faces randomized confirmation, while Sling's $123M financing advances oral linsitinib for thyroid eye di…
2 days, 5 hours ago
Vera’s Kidney Data Strengthen Full-Approval Case & Curium Challenges Novartis’ Lutathera
Season 1 Episode 172
Vera reports a 76% reduction in composite kidney-disease progression risk and near-stable two-year kidney function for TRUTAKNA (atacicept-vymj) in s…
3 days, 12 hours ago
Daily Roundup | Enhertu Delays Lung Cancer Progression, Survival Benefit Unproven
Season 1
Enhertu delayed lung cancer progression in a Phase 3 trial, but immature survival results and fatal lung toxicity complicate the first-line case. Def…
4 days, 8 hours ago
Week in Review | AstraZeneca’s Setback, Novartis Under Pressure & Scholar Rock’s Approval
AstraZeneca's broader-use trial of Etcamah (camizestrant)missed its primary goal in advanced breast cancer, while the existing approval stands. Schol…
5 days, 14 hours ago
Exelixis Faces FDA Delay & Karyopharm Faces October Deadline
Season 1 Episode 171
FDA extended its review of Exelixis's zanzalintinib-Tecentriq combination for metastatic colorectal cancer to March 3, 2027, after classifying update…
1 week ago
Biohaven Faces FDA Enrollment Hold & AbbVie Reports Menstrual Migraine Results
Season 1 Episode 170
Biohaven's FDA partial hold pauses new epilepsy-trialenrollment; the company still expects RISE-3 results this year. AbbVie reports LUNA menstrual-mi…
1 week, 1 day ago
Bayer's Hyrnuo Enters First-Line Rivalry & FDA Gets Permanent Center Chiefs
Season 1 Episode 169
Bayer's Hyrnuo (sevabertinib) gains first-line accelerated approval in HER2-mutant lung cancer, joining an established rival. Permanent FDA center le…
1 week, 2 days ago
Novartis's HARBOR Miss Tests Confidence in the Growth Plan & Rasonque's Access Hurdles
Season 1 Episode 168
Novartis's del-desiran missed HARBOR's primary endpoint in myotonic dystrophy, adding pressure to a growth plan already facing setbacks. Roivant and …
1 week, 3 days ago